0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Targeted Drug ALK Inhibitors for NSCLC Market Research Report 2025
Published Date: September 2025
|
Report Code: QYRE-Auto-9F6123
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global Targeted Drug ALK Inhibitors for NSCLC Market Insights and Forecast to 2028
BUY CHAPTERS

Global Targeted Drug ALK Inhibitors for NSCLC Market Research Report 2025

Code: QYRE-Auto-9F6123
Report
September 2025
Pages:75
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Targeted Drug ALK Inhibitors for NSCLC Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

Targeted Drug ALK Inhibitors for NSCLC Market

Targeted Drug ALK Inhibitors for NSCLC Market

The global market for Targeted Drug ALK Inhibitors for NSCLC was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Targeted Drug ALK Inhibitors for NSCLC are a new class of drugs that have been developed to specifically target abnormalities in the ALK gene that occur in some cases of non-small cell lung cancer (NSCLC). These drugs work by blocking the activity of the ALK protein, which may help to slow or stop the growth of cancer cells. There are several different types of ALK inhibitors, including crizotinib, ceritinib, alectinib, brigatinib, lorlatinib, and others.
The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Targeted Drug ALK Inhibitors for NSCLC, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Targeted Drug ALK Inhibitors for NSCLC.
The Targeted Drug ALK Inhibitors for NSCLC market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Targeted Drug ALK Inhibitors for NSCLC market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Targeted Drug ALK Inhibitors for NSCLC companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation

Scope of Targeted Drug ALK Inhibitors for NSCLC Market Report

Report Metric Details
Report Name Targeted Drug ALK Inhibitors for NSCLC Market
CAGR 5%
Segment by Type
  • Crizotinib
  • Ceritinib
  • Alectinib
  • Brigatinib
  • Lorlatinib
  • Others
Segment by Application
  • Squamous Cell Carcinoma of NSCLC
  • Adenocarcinoma of NSCLC
  • Large Cell Carcinoma of NSCLC
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Pfizer, Novartis, Chugai Pharmaceutical (Hoffmann-La Roche group), ARIAD Pharmaceuticals (Takeda), Genvio Pharma Limited, Beacon Pharma Limited, Drug International Limted, Incepta Pharmaceuticals
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
  • Chapter 3: Detailed analysis of Targeted Drug ALK Inhibitors for NSCLC company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
  • Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Targeted Drug ALK Inhibitors for NSCLC Market report?

Ans: The main players in the Targeted Drug ALK Inhibitors for NSCLC Market are Pfizer, Novartis, Chugai Pharmaceutical (Hoffmann-La Roche group), ARIAD Pharmaceuticals (Takeda), Genvio Pharma Limited, Beacon Pharma Limited, Drug International Limted, Incepta Pharmaceuticals

What are the Application segmentation covered in the Targeted Drug ALK Inhibitors for NSCLC Market report?

Ans: The Applications covered in the Targeted Drug ALK Inhibitors for NSCLC Market report are Squamous Cell Carcinoma of NSCLC, Adenocarcinoma of NSCLC, Large Cell Carcinoma of NSCLC

What are the Type segmentation covered in the Targeted Drug ALK Inhibitors for NSCLC Market report?

Ans: The Types covered in the Targeted Drug ALK Inhibitors for NSCLC Market report are Crizotinib, Ceritinib, Alectinib, Brigatinib, Lorlatinib, Others

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Targeted Drug ALK Inhibitors for NSCLC Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Crizotinib
1.2.3 Ceritinib
1.2.4 Alectinib
1.2.5 Brigatinib
1.2.6 Lorlatinib
1.2.7 Others
1.3 Market by Application
1.3.1 Global Targeted Drug ALK Inhibitors for NSCLC Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Squamous Cell Carcinoma of NSCLC
1.3.3 Adenocarcinoma of NSCLC
1.3.4 Large Cell Carcinoma of NSCLC
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Targeted Drug ALK Inhibitors for NSCLC Market Perspective (2020-2031)
2.2 Global Targeted Drug ALK Inhibitors for NSCLC Growth Trends by Region
2.2.1 Global Targeted Drug ALK Inhibitors for NSCLC Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Targeted Drug ALK Inhibitors for NSCLC Historic Market Size by Region (2020-2025)
2.2.3 Targeted Drug ALK Inhibitors for NSCLC Forecasted Market Size by Region (2026-2031)
2.3 Targeted Drug ALK Inhibitors for NSCLC Market Dynamics
2.3.1 Targeted Drug ALK Inhibitors for NSCLC Industry Trends
2.3.2 Targeted Drug ALK Inhibitors for NSCLC Market Drivers
2.3.3 Targeted Drug ALK Inhibitors for NSCLC Market Challenges
2.3.4 Targeted Drug ALK Inhibitors for NSCLC Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Targeted Drug ALK Inhibitors for NSCLC Players by Revenue
3.1.1 Global Top Targeted Drug ALK Inhibitors for NSCLC Players by Revenue (2020-2025)
3.1.2 Global Targeted Drug ALK Inhibitors for NSCLC Revenue Market Share by Players (2020-2025)
3.2 Global Targeted Drug ALK Inhibitors for NSCLC Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Targeted Drug ALK Inhibitors for NSCLC Revenue
3.4 Global Targeted Drug ALK Inhibitors for NSCLC Market Concentration Ratio
3.4.1 Global Targeted Drug ALK Inhibitors for NSCLC Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Targeted Drug ALK Inhibitors for NSCLC Revenue in 2024
3.5 Global Key Players of Targeted Drug ALK Inhibitors for NSCLC Head office and Area Served
3.6 Global Key Players of Targeted Drug ALK Inhibitors for NSCLC, Product and Application
3.7 Global Key Players of Targeted Drug ALK Inhibitors for NSCLC, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Targeted Drug ALK Inhibitors for NSCLC Breakdown Data by Type
4.1 Global Targeted Drug ALK Inhibitors for NSCLC Historic Market Size by Type (2020-2025)
4.2 Global Targeted Drug ALK Inhibitors for NSCLC Forecasted Market Size by Type (2026-2031)
5 Targeted Drug ALK Inhibitors for NSCLC Breakdown Data by Application
5.1 Global Targeted Drug ALK Inhibitors for NSCLC Historic Market Size by Application (2020-2025)
5.2 Global Targeted Drug ALK Inhibitors for NSCLC Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Targeted Drug ALK Inhibitors for NSCLC Market Size (2020-2031)
6.2 North America Targeted Drug ALK Inhibitors for NSCLC Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Targeted Drug ALK Inhibitors for NSCLC Market Size by Country (2020-2025)
6.4 North America Targeted Drug ALK Inhibitors for NSCLC Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Targeted Drug ALK Inhibitors for NSCLC Market Size (2020-2031)
7.2 Europe Targeted Drug ALK Inhibitors for NSCLC Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Targeted Drug ALK Inhibitors for NSCLC Market Size by Country (2020-2025)
7.4 Europe Targeted Drug ALK Inhibitors for NSCLC Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Targeted Drug ALK Inhibitors for NSCLC Market Size (2020-2031)
8.2 Asia-Pacific Targeted Drug ALK Inhibitors for NSCLC Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Targeted Drug ALK Inhibitors for NSCLC Market Size by Region (2020-2025)
8.4 Asia-Pacific Targeted Drug ALK Inhibitors for NSCLC Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Targeted Drug ALK Inhibitors for NSCLC Market Size (2020-2031)
9.2 Latin America Targeted Drug ALK Inhibitors for NSCLC Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Targeted Drug ALK Inhibitors for NSCLC Market Size by Country (2020-2025)
9.4 Latin America Targeted Drug ALK Inhibitors for NSCLC Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Targeted Drug ALK Inhibitors for NSCLC Market Size (2020-2031)
10.2 Middle East & Africa Targeted Drug ALK Inhibitors for NSCLC Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Targeted Drug ALK Inhibitors for NSCLC Market Size by Country (2020-2025)
10.4 Middle East & Africa Targeted Drug ALK Inhibitors for NSCLC Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Details
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Targeted Drug ALK Inhibitors for NSCLC Introduction
11.1.4 Pfizer Revenue in Targeted Drug ALK Inhibitors for NSCLC Business (2020-2025)
11.1.5 Pfizer Recent Development
11.2 Novartis
11.2.1 Novartis Company Details
11.2.2 Novartis Business Overview
11.2.3 Novartis Targeted Drug ALK Inhibitors for NSCLC Introduction
11.2.4 Novartis Revenue in Targeted Drug ALK Inhibitors for NSCLC Business (2020-2025)
11.2.5 Novartis Recent Development
11.3 Chugai Pharmaceutical (Hoffmann-La Roche group)
11.3.1 Chugai Pharmaceutical (Hoffmann-La Roche group) Company Details
11.3.2 Chugai Pharmaceutical (Hoffmann-La Roche group) Business Overview
11.3.3 Chugai Pharmaceutical (Hoffmann-La Roche group) Targeted Drug ALK Inhibitors for NSCLC Introduction
11.3.4 Chugai Pharmaceutical (Hoffmann-La Roche group) Revenue in Targeted Drug ALK Inhibitors for NSCLC Business (2020-2025)
11.3.5 Chugai Pharmaceutical (Hoffmann-La Roche group) Recent Development
11.4 ARIAD Pharmaceuticals (Takeda)
11.4.1 ARIAD Pharmaceuticals (Takeda) Company Details
11.4.2 ARIAD Pharmaceuticals (Takeda) Business Overview
11.4.3 ARIAD Pharmaceuticals (Takeda) Targeted Drug ALK Inhibitors for NSCLC Introduction
11.4.4 ARIAD Pharmaceuticals (Takeda) Revenue in Targeted Drug ALK Inhibitors for NSCLC Business (2020-2025)
11.4.5 ARIAD Pharmaceuticals (Takeda) Recent Development
11.5 Genvio Pharma Limited
11.5.1 Genvio Pharma Limited Company Details
11.5.2 Genvio Pharma Limited Business Overview
11.5.3 Genvio Pharma Limited Targeted Drug ALK Inhibitors for NSCLC Introduction
11.5.4 Genvio Pharma Limited Revenue in Targeted Drug ALK Inhibitors for NSCLC Business (2020-2025)
11.5.5 Genvio Pharma Limited Recent Development
11.6 Beacon Pharma Limited
11.6.1 Beacon Pharma Limited Company Details
11.6.2 Beacon Pharma Limited Business Overview
11.6.3 Beacon Pharma Limited Targeted Drug ALK Inhibitors for NSCLC Introduction
11.6.4 Beacon Pharma Limited Revenue in Targeted Drug ALK Inhibitors for NSCLC Business (2020-2025)
11.6.5 Beacon Pharma Limited Recent Development
11.7 Drug International Limted
11.7.1 Drug International Limted Company Details
11.7.2 Drug International Limted Business Overview
11.7.3 Drug International Limted Targeted Drug ALK Inhibitors for NSCLC Introduction
11.7.4 Drug International Limted Revenue in Targeted Drug ALK Inhibitors for NSCLC Business (2020-2025)
11.7.5 Drug International Limted Recent Development
11.8 Incepta Pharmaceuticals
11.8.1 Incepta Pharmaceuticals Company Details
11.8.2 Incepta Pharmaceuticals Business Overview
11.8.3 Incepta Pharmaceuticals Targeted Drug ALK Inhibitors for NSCLC Introduction
11.8.4 Incepta Pharmaceuticals Revenue in Targeted Drug ALK Inhibitors for NSCLC Business (2020-2025)
11.8.5 Incepta Pharmaceuticals Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
 Table 1. Global Targeted Drug ALK Inhibitors for NSCLC Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
 Table 2. Key Players of Crizotinib
 Table 3. Key Players of Ceritinib
 Table 4. Key Players of Alectinib
 Table 5. Key Players of Brigatinib
 Table 6. Key Players of Lorlatinib
 Table 7. Key Players of Others
 Table 8. Global Targeted Drug ALK Inhibitors for NSCLC Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
 Table 9. Global Targeted Drug ALK Inhibitors for NSCLC Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 10. Global Targeted Drug ALK Inhibitors for NSCLC Market Size by Region (2020-2025) & (US$ Million)
 Table 11. Global Targeted Drug ALK Inhibitors for NSCLC Market Share by Region (2020-2025)
 Table 12. Global Targeted Drug ALK Inhibitors for NSCLC Forecasted Market Size by Region (2026-2031) & (US$ Million)
 Table 13. Global Targeted Drug ALK Inhibitors for NSCLC Market Share by Region (2026-2031)
 Table 14. Targeted Drug ALK Inhibitors for NSCLC Market Trends
 Table 15. Targeted Drug ALK Inhibitors for NSCLC Market Drivers
 Table 16. Targeted Drug ALK Inhibitors for NSCLC Market Challenges
 Table 17. Targeted Drug ALK Inhibitors for NSCLC Market Restraints
 Table 18. Global Targeted Drug ALK Inhibitors for NSCLC Revenue by Players (2020-2025) & (US$ Million)
 Table 19. Global Targeted Drug ALK Inhibitors for NSCLC Market Share by Players (2020-2025)
 Table 20. Global Top Targeted Drug ALK Inhibitors for NSCLC Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Targeted Drug ALK Inhibitors for NSCLC as of 2024)
 Table 21. Ranking of Global Top Targeted Drug ALK Inhibitors for NSCLC Companies by Revenue (US$ Million) in 2024
 Table 22. Global 5 Largest Players Market Share by Targeted Drug ALK Inhibitors for NSCLC Revenue (CR5 and HHI) & (2020-2025)
 Table 23. Global Key Players of Targeted Drug ALK Inhibitors for NSCLC, Headquarters and Area Served
 Table 24. Global Key Players of Targeted Drug ALK Inhibitors for NSCLC, Product and Application
 Table 25. Global Key Players of Targeted Drug ALK Inhibitors for NSCLC, Date of Enter into This Industry
 Table 26. Mergers & Acquisitions, Expansion Plans
 Table 27. Global Targeted Drug ALK Inhibitors for NSCLC Market Size by Type (2020-2025) & (US$ Million)
 Table 28. Global Targeted Drug ALK Inhibitors for NSCLC Revenue Market Share by Type (2020-2025)
 Table 29. Global Targeted Drug ALK Inhibitors for NSCLC Forecasted Market Size by Type (2026-2031) & (US$ Million)
 Table 30. Global Targeted Drug ALK Inhibitors for NSCLC Revenue Market Share by Type (2026-2031)
 Table 31. Global Targeted Drug ALK Inhibitors for NSCLC Market Size by Application (2020-2025) & (US$ Million)
 Table 32. Global Targeted Drug ALK Inhibitors for NSCLC Revenue Market Share by Application (2020-2025)
 Table 33. Global Targeted Drug ALK Inhibitors for NSCLC Forecasted Market Size by Application (2026-2031) & (US$ Million)
 Table 34. Global Targeted Drug ALK Inhibitors for NSCLC Revenue Market Share by Application (2026-2031)
 Table 35. North America Targeted Drug ALK Inhibitors for NSCLC Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 36. North America Targeted Drug ALK Inhibitors for NSCLC Market Size by Country (2020-2025) & (US$ Million)
 Table 37. North America Targeted Drug ALK Inhibitors for NSCLC Market Size by Country (2026-2031) & (US$ Million)
 Table 38. Europe Targeted Drug ALK Inhibitors for NSCLC Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 39. Europe Targeted Drug ALK Inhibitors for NSCLC Market Size by Country (2020-2025) & (US$ Million)
 Table 40. Europe Targeted Drug ALK Inhibitors for NSCLC Market Size by Country (2026-2031) & (US$ Million)
 Table 41. Asia-Pacific Targeted Drug ALK Inhibitors for NSCLC Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 42. Asia-Pacific Targeted Drug ALK Inhibitors for NSCLC Market Size by Region (2020-2025) & (US$ Million)
 Table 43. Asia-Pacific Targeted Drug ALK Inhibitors for NSCLC Market Size by Region (2026-2031) & (US$ Million)
 Table 44. Latin America Targeted Drug ALK Inhibitors for NSCLC Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 45. Latin America Targeted Drug ALK Inhibitors for NSCLC Market Size by Country (2020-2025) & (US$ Million)
 Table 46. Latin America Targeted Drug ALK Inhibitors for NSCLC Market Size by Country (2026-2031) & (US$ Million)
 Table 47. Middle East & Africa Targeted Drug ALK Inhibitors for NSCLC Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 48. Middle East & Africa Targeted Drug ALK Inhibitors for NSCLC Market Size by Country (2020-2025) & (US$ Million)
 Table 49. Middle East & Africa Targeted Drug ALK Inhibitors for NSCLC Market Size by Country (2026-2031) & (US$ Million)
 Table 50. Pfizer Company Details
 Table 51. Pfizer Business Overview
 Table 52. Pfizer Targeted Drug ALK Inhibitors for NSCLC Product
 Table 53. Pfizer Revenue in Targeted Drug ALK Inhibitors for NSCLC Business (2020-2025) & (US$ Million)
 Table 54. Pfizer Recent Development
 Table 55. Novartis Company Details
 Table 56. Novartis Business Overview
 Table 57. Novartis Targeted Drug ALK Inhibitors for NSCLC Product
 Table 58. Novartis Revenue in Targeted Drug ALK Inhibitors for NSCLC Business (2020-2025) & (US$ Million)
 Table 59. Novartis Recent Development
 Table 60. Chugai Pharmaceutical (Hoffmann-La Roche group) Company Details
 Table 61. Chugai Pharmaceutical (Hoffmann-La Roche group) Business Overview
 Table 62. Chugai Pharmaceutical (Hoffmann-La Roche group) Targeted Drug ALK Inhibitors for NSCLC Product
 Table 63. Chugai Pharmaceutical (Hoffmann-La Roche group) Revenue in Targeted Drug ALK Inhibitors for NSCLC Business (2020-2025) & (US$ Million)
 Table 64. Chugai Pharmaceutical (Hoffmann-La Roche group) Recent Development
 Table 65. ARIAD Pharmaceuticals (Takeda) Company Details
 Table 66. ARIAD Pharmaceuticals (Takeda) Business Overview
 Table 67. ARIAD Pharmaceuticals (Takeda) Targeted Drug ALK Inhibitors for NSCLC Product
 Table 68. ARIAD Pharmaceuticals (Takeda) Revenue in Targeted Drug ALK Inhibitors for NSCLC Business (2020-2025) & (US$ Million)
 Table 69. ARIAD Pharmaceuticals (Takeda) Recent Development
 Table 70. Genvio Pharma Limited Company Details
 Table 71. Genvio Pharma Limited Business Overview
 Table 72. Genvio Pharma Limited Targeted Drug ALK Inhibitors for NSCLC Product
 Table 73. Genvio Pharma Limited Revenue in Targeted Drug ALK Inhibitors for NSCLC Business (2020-2025) & (US$ Million)
 Table 74. Genvio Pharma Limited Recent Development
 Table 75. Beacon Pharma Limited Company Details
 Table 76. Beacon Pharma Limited Business Overview
 Table 77. Beacon Pharma Limited Targeted Drug ALK Inhibitors for NSCLC Product
 Table 78. Beacon Pharma Limited Revenue in Targeted Drug ALK Inhibitors for NSCLC Business (2020-2025) & (US$ Million)
 Table 79. Beacon Pharma Limited Recent Development
 Table 80. Drug International Limted Company Details
 Table 81. Drug International Limted Business Overview
 Table 82. Drug International Limted Targeted Drug ALK Inhibitors for NSCLC Product
 Table 83. Drug International Limted Revenue in Targeted Drug ALK Inhibitors for NSCLC Business (2020-2025) & (US$ Million)
 Table 84. Drug International Limted Recent Development
 Table 85. Incepta Pharmaceuticals Company Details
 Table 86. Incepta Pharmaceuticals Business Overview
 Table 87. Incepta Pharmaceuticals Targeted Drug ALK Inhibitors for NSCLC Product
 Table 88. Incepta Pharmaceuticals Revenue in Targeted Drug ALK Inhibitors for NSCLC Business (2020-2025) & (US$ Million)
 Table 89. Incepta Pharmaceuticals Recent Development
 Table 90. Research Programs/Design for This Report
 Table 91. Key Data Information from Secondary Sources
 Table 92. Key Data Information from Primary Sources
 Table 93. Authors List of This Report


List of Figures
 Figure 1. Targeted Drug ALK Inhibitors for NSCLC Picture
 Figure 2. Global Targeted Drug ALK Inhibitors for NSCLC Market Size Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Targeted Drug ALK Inhibitors for NSCLC Market Share by Type: 2024 VS 2031
 Figure 4. Crizotinib Features
 Figure 5. Ceritinib Features
 Figure 6. Alectinib Features
 Figure 7. Brigatinib Features
 Figure 8. Lorlatinib Features
 Figure 9. Others Features
 Figure 10. Global Targeted Drug ALK Inhibitors for NSCLC Market Size by Application (2020-2031) & (US$ Million)
 Figure 11. Global Targeted Drug ALK Inhibitors for NSCLC Market Share by Application: 2024 VS 2031
 Figure 12. Squamous Cell Carcinoma of NSCLC Case Studies
 Figure 13. Adenocarcinoma of NSCLC Case Studies
 Figure 14. Large Cell Carcinoma of NSCLC Case Studies
 Figure 15. Targeted Drug ALK Inhibitors for NSCLC Report Years Considered
 Figure 16. Global Targeted Drug ALK Inhibitors for NSCLC Market Size (US$ Million), Year-over-Year: 2020-2031
 Figure 17. Global Targeted Drug ALK Inhibitors for NSCLC Market Size, (US$ Million), 2020 VS 2024 VS 2031
 Figure 18. Global Targeted Drug ALK Inhibitors for NSCLC Market Share by Region: 2024 VS 2031
 Figure 19. Global Targeted Drug ALK Inhibitors for NSCLC Market Share by Players in 2024
 Figure 20. Global Top Targeted Drug ALK Inhibitors for NSCLC Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Targeted Drug ALK Inhibitors for NSCLC as of 2024)
 Figure 21. The Top 10 and 5 Players Market Share by Targeted Drug ALK Inhibitors for NSCLC Revenue in 2024
 Figure 22. North America Targeted Drug ALK Inhibitors for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 23. North America Targeted Drug ALK Inhibitors for NSCLC Market Share by Country (2020-2031)
 Figure 24. United States Targeted Drug ALK Inhibitors for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 25. Canada Targeted Drug ALK Inhibitors for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 26. Europe Targeted Drug ALK Inhibitors for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 27. Europe Targeted Drug ALK Inhibitors for NSCLC Market Share by Country (2020-2031)
 Figure 28. Germany Targeted Drug ALK Inhibitors for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 29. France Targeted Drug ALK Inhibitors for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 30. U.K. Targeted Drug ALK Inhibitors for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 31. Italy Targeted Drug ALK Inhibitors for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 32. Russia Targeted Drug ALK Inhibitors for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 33. Nordic Countries Targeted Drug ALK Inhibitors for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 34. Asia-Pacific Targeted Drug ALK Inhibitors for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 35. Asia-Pacific Targeted Drug ALK Inhibitors for NSCLC Market Share by Region (2020-2031)
 Figure 36. China Targeted Drug ALK Inhibitors for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 37. Japan Targeted Drug ALK Inhibitors for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 38. South Korea Targeted Drug ALK Inhibitors for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 39. Southeast Asia Targeted Drug ALK Inhibitors for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 40. India Targeted Drug ALK Inhibitors for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 41. Australia Targeted Drug ALK Inhibitors for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 42. Latin America Targeted Drug ALK Inhibitors for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 43. Latin America Targeted Drug ALK Inhibitors for NSCLC Market Share by Country (2020-2031)
 Figure 44. Mexico Targeted Drug ALK Inhibitors for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 45. Brazil Targeted Drug ALK Inhibitors for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 46. Middle East & Africa Targeted Drug ALK Inhibitors for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 47. Middle East & Africa Targeted Drug ALK Inhibitors for NSCLC Market Share by Country (2020-2031)
 Figure 48. Turkey Targeted Drug ALK Inhibitors for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 49. Saudi Arabia Targeted Drug ALK Inhibitors for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 50. UAE Targeted Drug ALK Inhibitors for NSCLC Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 51. Pfizer Revenue Growth Rate in Targeted Drug ALK Inhibitors for NSCLC Business (2020-2025)
 Figure 52. Novartis Revenue Growth Rate in Targeted Drug ALK Inhibitors for NSCLC Business (2020-2025)
 Figure 53. Chugai Pharmaceutical (Hoffmann-La Roche group) Revenue Growth Rate in Targeted Drug ALK Inhibitors for NSCLC Business (2020-2025)
 Figure 54. ARIAD Pharmaceuticals (Takeda) Revenue Growth Rate in Targeted Drug ALK Inhibitors for NSCLC Business (2020-2025)
 Figure 55. Genvio Pharma Limited Revenue Growth Rate in Targeted Drug ALK Inhibitors for NSCLC Business (2020-2025)
 Figure 56. Beacon Pharma Limited Revenue Growth Rate in Targeted Drug ALK Inhibitors for NSCLC Business (2020-2025)
 Figure 57. Drug International Limted Revenue Growth Rate in Targeted Drug ALK Inhibitors for NSCLC Business (2020-2025)
 Figure 58. Incepta Pharmaceuticals Revenue Growth Rate in Targeted Drug ALK Inhibitors for NSCLC Business (2020-2025)
 Figure 59. Bottom-up and Top-down Approaches for This Report
 Figure 60. Data Triangulation
 Figure 61. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Bioinformatics Barcelona

SIMILAR REPORTS